Intuitive Surgical Inc

Intuitive Surgical Inc

ISRG

Get informed when a big investor buys or sells

+ Follow
Market Cap$150.39B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Intuitive Surgical IncIntuitive Surgical Inc50.6-17%14-

Earnings Call Q1 2026

April 21, 2026 - AI Summary

Strong Revenue Growth: Intuitive reported Q1 2026 revenue of $2.77 billion, a 23% increase year-over-year. Recurring revenue accounted for 86% of total revenues, indicating a healthy business model. Total procedure growth was 17%, with da Vinci procedures increasing by 16% and Ion procedures by 39%.
Increased Utilization and Adoption: Da Vinci system utilization in the U.S. grew 4%, with after-hours procedures increasing by 31%. Da Vinci 5 utilization exceeded that of the older Xi model, encouraging broader adoption among surgeons. This trend suggests potential for continued procedure growth, which is essential for future system placements.
Optimistic 2026 Growth Forecast: The company raised its full-year 2026 da Vinci procedure growth forecast to 13.5% to 15.5%, up from the previous range of 13% to 15%. The primary growth drivers continue to be general surgery in the U.S. and procedures outside of urology internationally.

Exclusive for Stockcircle Pro members

Sign upSign Up
$576.80

Target Price by Analysts

41.6% upsideIntuitive Surgical Target Price DetailsTarget Price
$130.62

Current Fair Value

67.9% downside

Overvalued by 67.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$150.39 Billion
Enterprise Value$143.08 Billion
Dividend Yield$- (-)
Earnings per Share$8
Beta1.51
Outstanding Shares354,900,000

Return

Return on Equity17.05%ROE
Return on Assets14.81%
Return on Invested Capital17.99%

Valuation & Multiples

P/E Ratio50.59P/E Ratio
PEG287PEG
Price to Sales14.04Price to Sales
Price to Book Ratio8.31Price to Book Ratio
Enterprise Value to Revenue13.52
Enterprise Value to EBIT40.9
Enterprise Value to Net Income48
Total Debt to Enterprise0
Debt to Equity0.04Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 28, 2026
EPS Estimate
$2.08
Average shareholder expectation
Revenue Estimate
$2.62 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 28, 2026
EPS Estimate
$2.48
Average shareholder expectation
Revenue Estimate
$2.82 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio1.1163 14.69%
Total Calls2,849,489 10.44%
Total Puts3,180,897 20.86%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %82.39% 1.83%
Total Invested$135.05B 20.00%
Investors Holding2,374 115.00%

ESG Score

No data

About Intuitive Surgical Inc

CEO: Gary Guthart

Relevant Senate Committees

Joint Committee on Taxation

This committee directly influences the development and analysis of tax legislation, providing crucial revenue estimates. Its work directly impacts corporate tax structures and the overall tax burden on companies like Intuitive Surgical.

Finance

This powerful committee controls taxation, trade, and entitlement spending. Medicare and Medicaid reimbursement policies are critical for healthcare providers and, by extension, medical device manufacturers. Tax policy directly impacts ISRG's profitability.

Appropriations

This committee directly allocates federal spending. Its subcommittees determine funding for healthcare programs (e.g., NIH, VA) and scientific research, which directly impacts the market and R&D opportunities for medical device manufacturers like ISRG.

Health, Education, Labor, and Pensions

This committee regulates the FDA, which is the primary approval body for medical devices. Its oversight of NIH funding impacts medical research, and labor laws affect manufacturing costs, all directly critical to ISRG's business.

Judiciary

This committee's oversight of intellectual property laws is crucial for ISRG, which relies heavily on patents for its surgical robotics. Its antitrust jurisdiction can also influence M&A and market competition within the medical device industry.

Veterans' Affairs

As a manufacturer of surgical instruments, ISRG's products are likely used in VA hospitals. The committee's funding decisions directly impact government healthcare contractors and medical device procurement for veterans.